Kenji Kabashima

Research interests

Publications

• Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

  Allergy · 2023 · https://doi.org/10.1111/all.15889

• Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents

  Journal of Dermatological Science · 2021 · https://doi.org/10.1016/j.jdermsci.2021.04.007

• Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2021 · 10.1016/s0140-6736(21)00589-4

• Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council

  Journal of Allergy and Clinical Immunology · 2021 · 10.1016/j.jaci.2021.01.013

• Type 2 immunity in the skin and lungs

  Allergy · 2020 · 10.1111/all.14318

• Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

  British Journal of Dermatology · 2020 · https://doi.org/10.1111/bjd.18898

• Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus

  New England Journal of Medicine · 2020 · 10.1056/nejmoa1917006

• Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches

  Science · 2019 · https://doi.org/10.1126/science.aau0964

• The immunological anatomy of the skin

  Nature reviews. Immunology · 2018 · 10.1038/s41577-018-0084-5

• Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study

  Journal of Allergy and Clinical Immunology · 2018 · https://doi.org/10.1016/j.jaci.2018.03.018

• The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis

  Nature Immunology · 2018 · 10.1038/s41590-018-0256-2

• Atopic dermatitis

  Nature Reviews Disease Primers · 2018 · https://doi.org/10.1038/s41572-018-0001-z

• Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

  Frontiers in Oncology · 2018 · https://doi.org/10.3389/fonc.2018.00086

• Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1606490

• Germline NLRP1 Mutations Cause Skin Inflammatory and Cancer Susceptibility Syndromes via Inflammasome Activation

  Cell · 2016 · 10.1016/j.cell.2016.09.001

• Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder

  Journal of Investigative Dermatology · 2016 · 10.1016/j.jid.2016.08.022

• The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization

  Journal of Allergy and Clinical Immunology · 2015 · 10.1016/j.jaci.2015.08.015

• New concept of the pathogenesis of atopic dermatitis: Interplay among the barrier, allergy, and pruritus as a trinity

  Journal of Dermatological Science · 2013 · 10.1016/j.jdermsci.2013.02.001

• Update of Immune Events in the Murine Contact Hypersensitivity Model: Toward the Understanding of Allergic Contact Dermatitis

  Journal of Investigative Dermatology · 2012 · 10.1038/jid.2012.284

• Stress-induced production of chemokines by hair follicles regulates the trafficking of dendritic cells in skin

  Nature Immunology · 2012 · 10.1038/ni.2353

• Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

  Cancer · 2010 · 10.1002/cncr.24899

• Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis

  Journal of Investigative Dermatology · 2008 · 10.1038/jid.2008.111

• Intrinsic Lymphotoxin-β Receptor Requirement for Homeostasis of Lymphoid Tissue Dendritic Cells

  Immunity · 2005 · 10.1016/j.immuni.2005.02.007

• Prostaglandin E2–EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells

  Nature Medicine · 2003 · 10.1038/nm872

• The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut

  Journal of Clinical Investigation · 2002 · 10.1172/jci0214459

• The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut

  Journal of Clinical Investigation · 2002 · 10.1172/jci14459

• Prostaglandin D 2 as a Mediator of Allergic Asthma

  Science · 2000 · 10.1126/science.287.5460.2013

Current projects

No projects listed.